2020 Korean guidelines for the management of metastatic prostate cancer
- Authors
- Kim, In-Ho; Shin, Sang Joon; Kang, Byung Woog; Kang, Jihoon; Kim, Dalyong; Kim, Miso; Kim, Jin Young; Kim, Chan Kyu; Kim, Hee-Jun; Maeng, Chi Hoon; Park, Kwonoh; Park, Inkeun; Bae, Woo Kyun; Sohn, Byeong Seok; Lee, Min-Young; Lee, Jae Lyun; Lee, Junglim; Lim, Seung Taek; Lim, Joo Han; Chang, Hyun; Jung, Joo Young; Choi, Yoon Ji; Kim, Young Seok; Cho, Jaeho; Joung, Jae Young; Park, Se Hoon; Lee, Hyo Jin
- Issue Date
- 5월-2021
- Publisher
- KOREAN ASSOC INTERNAL MEDICINE
- Keywords
- Practice guideline; Prostate neoplasms
- Citation
- KOREAN JOURNAL OF INTERNAL MEDICINE, v.36, no.3, pp.491 - 514
- Indexed
- SCIE
SCOPUS
KCI
- Journal Title
- KOREAN JOURNAL OF INTERNAL MEDICINE
- Volume
- 36
- Number
- 3
- Start Page
- 491
- End Page
- 514
- URI
- https://scholar.korea.ac.kr/handle/2021.sw.korea/128117
- DOI
- 10.3904/kjim.2020.213
- ISSN
- 1226-3303
- Abstract
- In 2017, Korean Society of Medical Oncology (KSMO) published the Korean management guideline of metastatic prostate cancer. This paper is the 2nd edition of the Korean management guideline of metastatic prostate cancer. We updated recent many changes of management in metastatic prostate cancer in this 2nd edition guideline. The present guideline consists of the three categories: management of metastatic hormone sensitive prostate cancer; management of metastatic castration resistant prostate cancer; and clinical consideration for treating patients with metastatic prostate cancer. In category 1 and 2, levels of evidence (LEs) have been mentioned according to the general principles of evidence-based medicine. And grades of recommendation (GR) was taken into account the quality of evidence, the balance between desirable and undesirable effects, the values and preferences, and the use of resources and GR were divided into strong recommendations (SR) and weak recommendations (WR). A total of 16 key questions are selected. And we proposed recommendations and described key evidence for each recommendation. The treatment landscape of metastatic prostate cancer is changing very rapid and many trials are ongoing. To verify the results of the future trials is necessary and should be applied to the treatment for metastatic prostate cancer patients in the clinical practice. Especially, many prostate cancer patients are old age, have multiple underlying medical comorbidities, clinicians should be aware of the significance of medical management as well as clinical efficacy of systemic treatment.Y
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - College of Medicine > Department of Medical Science > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.